| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 1, 2012Accelerates Globalization and Company's Overall Position in Global Orthopedics Market
MINNEAPOLIS, Nov. 1, 2012 - Medtronic, Inc. (NYSE: MDT) announced today that it has completed its acquisition of China Kanghui Holdings (NYSE: KH), a leading provider of orthopedic devices in...
-
Oct 29, 2012Data Demonstrate High Procedural Success in Late-Breaking Trials Session at the European Association for Cardio-Thoracic Surgery Annual Meeting
MINNEAPOLIS - October 29, 2012 - Medtronic, Inc. (NYSE: MDT) today announced promising data from the EngagerTM European Pivotal Trial for the investigational Medtronic EngagerTM Transcatheter...
-
Oct 29, 2012Data Demonstrate High Procedural Success in Late-Breaking Trials Session at the European Association for Cardio-Thoracic Surgery Annual Meeting
MINNEAPOLIS - October 29, 2012 - Medtronic, Inc. (NYSE: MDT) today announced promising data from the EngagerTM European Pivotal Trial for the investigational Medtronic EngagerTM Transcatheter...
-
Oct 29, 2012Data Demonstrate High Procedural Success in Late-Breaking Trials Session at the European Association for Cardio-Thoracic Surgery Annual Meeting
MINNEAPOLIS - October 29, 2012 - Medtronic, Inc. (NYSE: MDT) today announced promising data from the EngagerTM European Pivotal Trial for the investigational Medtronic EngagerTM Transcatheter...
-
Sep 27, 2012Acquisition Advances Medtronic's Globalization Strategy; Provides Strong Local China Operation as well as Broader Orthopedics Participation
MINNEAPOLIS and CHANGZHOU, CHINA - Sept. 27, 2012 - Medtronic, Inc. (NYSE: MDT) and China Kanghui Holdings (NYSE: KH) announced today that they have entered into a merger agreement whereby...
-
Aug 21, 2012Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported
MINNEAPOLIS - August 21, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide...
-
Jun 21, 2012
MINNEAPOLIS - June 21, 2012 - The board of directors of Medtronic, Inc. (NYSE: MDT) today approved a 7.2 percent increase in its cash dividend for fiscal year 2013, raising the quarterly amount to...
-
May 31, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 31, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs 33rd Annual...
-
May 25, 2012Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up
MINNEAPOLIS--(BUSINESS WIRE)--May. 25, 2012-- According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists...
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
May 11, 2012Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 11, 2012-- Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in...
-
May 10, 2012Late-Breaking Clinical Trial Validates Medtronic Proprietary Device Algorithms
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from the first and only clinical trial to show that Medtronic cardiac devices can safely...
-
May 8, 2012Implantable Medical Device for Endovascular Repair of Thoracic Aortic Aneurysms Also Being Studied for Minimally Invasive Treatment of Blunt Thoracic Aortic Injuries
MINNEAPOLIS--(BUSINESS WIRE)--May. 8, 2012-- Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant®...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Mar 26, 2012ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
-
Mar 24, 2012Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes
CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
-
Mar 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
-
Mar 1, 2012“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 1, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the...
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve® System delivered...
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS, Jan 30, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve(R) System delivered...
-
Dec 23, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 23, 2011-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the 30th Annual JP Morgan...
-
Dec 9, 2011Neurostimulator with Innovative Motion Sensor Technology Was Recently Approved by the FDA for the Management of Chronic Pain
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 9, 2011-- Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStim™ with...
-
Nov 17, 2011
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE:MDT) and Bain Capital, a leading global private investment firm, today announced they have entered into a definitive...
-
Nov 8, 2011Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device's Consistently Positive Performance Across Multiple Clinical Studies
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT)...
-
Nov 8, 2011Final Five-Year Follow-up of Randomized ENDEAVOR IV Trial Shows Durable Safety and Efficacy of Endeavor DES, with Comparatively Lower Rates of Cardiac Death/Myocardial Infarction and Very Late Stent Thrombosis
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- New research findings released at TCT 2011 show that the Endeavor(R) zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed...